Faron Pharmaceuticals Oy (LON:FARN – Get Rating)’s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 321.76 ($3.92) and traded as high as GBX 327 ($3.99). Faron Pharmaceuticals Oy shares last traded at GBX 317.50 ($3.87), with a volume of 10,600 shares changing hands.
Faron Pharmaceuticals Oy Stock Performance
The company has a debt-to-equity ratio of 121.51, a quick ratio of 1.09 and a current ratio of 0.93. The stock has a 50 day moving average of GBX 321.76 and a 200 day moving average of GBX 257.31. The stock has a market capitalization of £201.61 million, a P/E ratio of -690.22 and a beta of 0.20.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.